MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme DIO Ratio 2011-2025 | EPZM
Annual DIO Ratio Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 754 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 754 | 754 | 754 |
Quarterly DIO Ratio Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 59.2 | 19.7 | 167 | 262 | 297 | 467 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 467 | 19.7 | 212 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
42.1 | $ 3.39 | 0.89 % | $ 262 M |  USA |
 |
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 1.28 | -3.76 % | $ 6.98 M |  China |
 |
AstraZeneca PLC
AZN
|
206 | $ 89.67 | -0.69 % | $ 96.9 B |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
132 | $ 25.58 | -1.24 % | $ 1.24 B | USA |
 |
Anika Therapeutics
ANIK
|
247 | $ 9.58 | 0.95 % | $ 140 M | USA |
 |
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Berkeley Lights
BLI
|
246 | - | -7.31 % | $ 87 M | USA |
 |
Biogen
BIIB
|
394 | $ 174.16 | 0.96 % | $ 25.4 B | USA |
 |
Aytu BioScience
AYTU
|
209 | $ 2.32 | 1.84 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
160 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
596 | - | 0.59 % | $ 63 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
114 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
116 | $ 573.81 | -1.24 % | $ 43.5 B | USA |
 |
Catalyst Biosciences
CBIO
|
410 | $ 15.24 | -0.46 % | $ 1 B | USA |
 |
Caladrius Biosciences
CLBS
|
35.8 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
2.04 K | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
239 | $ 11.52 | 0.7 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
213 | $ 2.23 | 3.49 % | $ 412 M | USA |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |